Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for ProText Mobility's Debt-to-EBITDA or its related term are showing as below:
TXTM's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.14 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
ProText Mobility Debt-to-EBITDA Related Terms
ProText Mobility Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for ProText Mobility's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TXTM vs DRSV, YPPN, CYBF: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, ProText Mobility's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProText Mobility Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ProText Mobility's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ProText Mobility's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Sep. 2014) EBITDA data.
ProText Mobility (TXTM) has a Debt-to-EBITDA of 29.58 as of Sep. 2014. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on ProText Mobility.
Is ProText Mobility's Debt-to-EBITDA too high?
ProText Mobility's current Debt-to-EBITDA is 29.58. The Biotechnology industry median Debt-to-EBITDA is 1.14. ProText Mobility's value of 29.58 is 2494.7% above this industry median.
How does ProText Mobility's Debt-to-EBITDA compare to DRSV and YPPN?
ProText Mobility's Debt-to-EBITDA of 29.58 can be compared against companies in the Biotechnology industry. The industry median Debt-to-EBITDA is 1.14. ProText Mobility's value of 29.58 is 2494.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ProText Mobility's current Debt-to-EBITDA of 29.58 is 2494.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on ProText Mobility. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProText Mobility's current Debt-to-EBITDA is 29.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProText Mobility stock overvalued right now?
ProText Mobility (TXTM) has a current Debt-to-EBITDA of 29.58. The current Debt-to-EBITDA is 29.58 and 2494.7% above the Biotechnology industry median of 1.14. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For ProText Mobility (TXTM), the current Debt-to-EBITDA is 29.58 as of Sep. 2014. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProText Mobility Inc is a Biotech Company developing a Hemp/CBD-Cannabis medicines platform for the legal cannabis industry, using proprietary live plant extraction processes and technologies. Protext has engaged in the research, testing, and development of bioavailable botanical products, all-natural ingredients formulated for nutraceuticals and pharmaceutical applications through proprietary live plant extraction technology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXTM has been successfully added to your 
